000128095 001__ 128095
000128095 005__ 20241125101159.0
000128095 0247_ $$2doi$$a10.1016/j.euroneuro.2023.06.003
000128095 0248_ $$2sideral$$a135272
000128095 037__ $$aART-2023-135272
000128095 041__ $$aeng
000128095 100__ $$aGonzález Segura, Àlex
000128095 245__ $$aThe polygenic basis of relapse after a first episode of schizophrenia
000128095 260__ $$c2023
000128095 5060_ $$aAccess copy available to the general public$$fUnrestricted
000128095 5203_ $$aLittle is known about genetic predisposition to relapse. Previous studies have linked cognitive and psychopathological (mainly schizophrenia and bipolar disorder) polygenic risk scores (PRS) with clinical manifestations of the disease. This study aims to explore the potential role of PRS from major mental disorders and cognition on schizophrenia relapse. 114 patients recruited in the 2EPs Project were included (56 patients who had not experienced relapse after 3 years of enrollment and 58 patients who relapsed during the 3-year follow-up). PRS for schizophrenia (PRS-SZ), bipolar disorder (PRS-BD), education attainment (PRS-EA) and cognitive performance (PRS-CP) were used to assess the genetic risk of schizophrenia relapse.Patients with higher PRS-EA, showed both a lower risk (OR=0.29, 95% CI [0.11–0.73]) and a later onset of relapse (30.96± 1.74 vs. 23.12± 1.14 months, p=0.007. Our study provides evidence that the genetic burden of neurocognitive function is a potentially predictors of relapse that could be incorporated into future risk prediction models. Moreover, appropriate treatments for cognitive symptoms appear to be important for improving the long-term clinical outcome of relapse.
000128095 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/PI08-0208$$9info:eu-repo/grantAgreement/ES/MINECO/PI11-00325$$9info:eu-repo/grantAgreement/ES/MINECO/PI16-00612
000128095 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000128095 590__ $$a6.1$$b2023
000128095 592__ $$a1.756$$b2023
000128095 591__ $$aCLINICAL NEUROLOGY$$b22 / 280 = 0.079$$c2023$$dQ1$$eT1
000128095 593__ $$aBiological Psychiatry$$c2023$$dQ1
000128095 591__ $$aPSYCHIATRY$$b21 / 279 = 0.075$$c2023$$dQ1$$eT1
000128095 593__ $$aNeurology$$c2023$$dQ1
000128095 591__ $$aPHARMACOLOGY & PHARMACY$$b26 / 354 = 0.073$$c2023$$dQ1$$eT1
000128095 593__ $$aPsychiatry and Mental Health$$c2023$$dQ1
000128095 591__ $$aNEUROSCIENCES$$b32 / 310 = 0.103$$c2023$$dQ1$$eT1
000128095 593__ $$aPharmacology$$c2023$$dQ1
000128095 593__ $$aPharmacology (medical)$$c2023$$dQ1
000128095 593__ $$aNeurology (clinical)$$c2023$$dQ1
000128095 594__ $$a10.3$$b2023
000128095 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000128095 700__ $$aProhens, Llucia
000128095 700__ $$aGassó, Patricia
000128095 700__ $$aRodríguez, Natalia
000128095 700__ $$aGarcia-Rizo, Clemente
000128095 700__ $$aMoreno-Izco, Lucía
000128095 700__ $$aAndreu-Bernabeu, Álvaro
000128095 700__ $$aZorrilla, Iñaki
000128095 700__ $$aMane, Anna
000128095 700__ $$aRodríguez-Jiménez, Roberto
000128095 700__ $$aRoldán, Alexandra
000128095 700__ $$aSarró, Salvador
000128095 700__ $$aIbáñez, Ángela
000128095 700__ $$aUsall, Judith
000128095 700__ $$aSáiz, Pilar A
000128095 700__ $$aCuesta, Manuel J.
000128095 700__ $$aParellada, Mara
000128095 700__ $$aGonzález-Pinto, Ana
000128095 700__ $$aBerrocoso, Ester
000128095 700__ $$aBernardo, Miquel
000128095 700__ $$aMas, Sergi
000128095 700__ $$aMezquida, Gisela
000128095 700__ $$aArbelo, Néstor
000128095 700__ $$aDe Matteis, Mario
000128095 700__ $$aGalvañ, Joaquín
000128095 700__ $$aDuque Guerra, Alejandra
000128095 700__ $$aArias i Queralt, Laia
000128095 700__ $$aPerez-Bacigalupe, Maria
000128095 700__ $$aGonzalez-Ortega, Itxaso
000128095 700__ $$aToll, Alba
000128095 700__ $$aCasanovas, Francesc
000128095 700__ $$aSanchez-Pastor, Luis
000128095 700__ $$aValtueña, Mercedes
000128095 700__ $$aPomarol-Clotet, Edith
000128095 700__ $$aGarcía-León, Maria Ángeles
000128095 700__ $$aButjosa, Ana
000128095 700__ $$aRubio-Abadal, Elena
000128095 700__ $$aRibeiro, María
000128095 700__ $$aLópez-Ilundain, Jose M.
000128095 700__ $$aSaiz-Ruiz, Jeronimo
000128095 700__ $$aLeón-Quismondo, Luis
000128095 700__ $$aRivero, Olga
000128095 700__ $$0(orcid)0000-0001-5940-0357$$aRuiz, Pedro$$uUniversidad de Zaragoza
000128095 700__ $$aEchevarría, Rafael Segarra
000128095 700__ $$aGarcía-Portilla, M. Paz
000128095 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría
000128095 773__ $$g75 (2023), 80-92$$pEur. neuropsychopharmacol.$$tEUROPEAN NEUROPSYCHOPHARMACOLOGY$$x0924-977X
000128095 8564_ $$s949946$$uhttps://zaguan.unizar.es/record/128095/files/texto_completo.pdf$$yVersión publicada
000128095 8564_ $$s2107821$$uhttps://zaguan.unizar.es/record/128095/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000128095 909CO $$ooai:zaguan.unizar.es:128095$$particulos$$pdriver
000128095 951__ $$a2024-11-22-12:10:57
000128095 980__ $$aARTICLE